New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
12:41 EDTPBH, LPNT, DV, AMZN, MSFT, F, CYTK, POn The Fly: Midday Wrap
Stocks on Wall Street were lower at midday, with the tech-heavy Nasdaq being weighed down by shares of Amazon (AMZN), which slid following the e-commerce giant's quarterly report. The market opened lower and picked up downside momentum to extend the slide to triple digit losses for the Dow and a more than 1% loss for the Nasdaq. The weakness comes in spite of a report that showed consumer confidence surged in April to approach the highest level since the recession began in 2007. ECONOMIC EVENTS: In the U.S., Markit's flash services PMI dipped 1.1 points to 54.2 in April, missing expectations for a rise to 55.5. The final University of Michigan consumer confidence reading for April rose to 84.1, beating expectations for a reading of 83.0. In Europe, S&P cut Russia's sovereign rating to BBB-. COMPANY NEWS: Shares of online retailer Amazon.com fell 9% after the company’s second quarter outlook failed to impress. After the company reported roughly in-line Q1 results and forecast Q2 revenue of $18.1B-$19.8B, compared to consensus of $19.03B, Citigroup, Wells Fargo, and Deutsche Bank all lowered their respective price targets on the stock. Another firm, Raymond James, downgraded Amazon to Outperform from Strong Buy, citing mixed Q1 results, a continued significant investment cycle, and slowing unit growth and media sales. The firm lowered its price target on the shares to $391 from $443... Microsoft (MSFT) shares were up nearly 1% after reporting earnings that beat expectations on revenues that were roughly in-line with estimates in the first quarter with new CEO Satya Nadella at the helm. MAJOR MOVERS: Among the notable gainers was Prestige Brands (PBH), which rose 17% after the company agreed to acquire Insight Pharmaceuticals for $750M. Also higher following their earnings reports were for-profit education company DeVry (DV), which gained 14%, and hospital operator LifePoint Hospitals (LPNT), which advanced 5%. Among the noteworthy losers was drugmaker Cytokinetics (CYTK), which plunged more than 60% after a trial of tirasemtiv in ALS did not achieve its primary efficacy endpoint. Also lower following their earnings reports were Internet radio provider Pandora (P), which fell over 15%, and carmaker Ford (F), which slid 3%. INDEXES: Near midday, the Dow was down 119.19, or 0.72%, to 16,382.46, the Nasdaq was down 58.29, or 1.41%, to 4,090.05, and the S&P 500 was down 11.91, or 0.63%, to 1,866.70.
News For PBH;LPNT;DV;AMZN;MSFT;F;CYTK;P From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>
October 20, 2014
12:09 EDTMSFTIBM hits 52 week low after earnings miss, 2015 profit target dropped
Subscribe for More Information
12:01 EDTAMZNNetflix, Amazon recomended as short ideas by Fred Wilson, Bloomberg reports
Subscribe for More Information
08:00 EDTMSFTRBC Capital remains positive on Microsoft
Subscribe for More Information
07:37 EDTCYTKCytokinetics completes review results from BENEFIT-ALS regarding tirasemtiv
Cytokinetics provided a program update today relating to tirasemtiv, the company's lead drug candidate from its skeletal muscle contractility program. The company announced that it has completed its review of results from BENEFIT-ALS and has concluded that effects observed on Slow Vital Capacity in patients treated with tirasemtiv are robust and potentially clinically meaningful. In addition, following consultation with clinical and statistical experts, the company believes that data from BENEFIT-ALS support progression of tirasemtiv to a potential Phase III clinical trial in patients with amyotrophic lateral sclerosis (ALS). The company also announced that it has begun regulatory interactions with the U.S. Food and Drug Administration regarding results from BENEFIT-ALS and has received initial feedback from the FDA. The company believes that effects on SVC could be a Phase III clinical trial endpoint and could support registration of tirasemtiv as a potential treatment for patients with ALS. As a result, Cytokinetics has initiated planning for a potential Phase III clinical trial of tirasemtiv that could begin in 2015. Cytokinetics has received feedback from the FDA following initial communications regarding tirasemtiv and BENEFIT-ALS. The company believes that the FDA may be willing to consider a potential registration path for tirasemtiv relating to effects on SVC. The company expects to have additional interactions with the FDA and other regulatory authorities. In addition, the company has commenced Phase III readiness activities including designing a potential Phase III clinical trial in order to inform plans, timelines and costs associated with the further development of tirasemtiv.
07:24 EDTPPandora expected to meet/beat high-end of Q3 guidance, says Wedbush
Subscribe for More Information
07:06 EDTMSFTNICE Systems solution qualified to support Microsoft Lync
Subscribe for More Information
06:09 EDTFFord expected to add over 300 new jobs at Dagenham plant, Guardian reports
Subscribe for More Information
05:59 EDTAMZNStocks with implied volatility above IV index mean; DISH AMZN
Subscribe for More Information
October 19, 2014
20:41 EDTMSFTMicrosoft plans smartwatch launch within weeks, Forbes says
Microsoft (MSFT) is planning a smart watch launch within the next few weeks, Forbes says.The smart watch will passively keep track of the wearer’s heart rate and work across different mobile platforms, added Forbes. Apple (AAPL) has delayed its own smartwatch launch to early 2015 according to the report. Reference Link
October 17, 2014
16:01 EDTAMZNOptions Update; October 17, 2014
iPath S&P 500 VIX Short-Term Futures down 1.75 to 38.58 Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX GILD CLF PBR according to Track Data.
14:39 EDTFFord to hold a conference call
Subscribe for More Information
11:27 EDTMSFTMicrosoft October weekly volatility elevated into Q1 and outlook
Subscribe for More Information
10:31 EDTPPandora calls active on renewed speculation of an activist investor
Subscribe for More Information
10:20 EDTPPandora spikes higher, levels to watch
Shares are up 3% to $22.70 on a sharp spike in the last ten minutes. At current price resistance is at $23.23. Support is at $22.45, the opening price of the day.
10:16 EDTPRumor: Pandora moves up on renewed speculation of an activist investor
Subscribe for More Information
09:22 EDTAMZNAmazon.com volatility elevated into Q3 and outlook
Subscribe for More Information
06:30 EDTMSFTNPD: Sony PlayStation4 outsells XBox One in September, GameSpot reports
Subscribe for More Information
06:26 EDTMSFTSony says PS4 September's top-selling console
Subscribe for More Information
06:22 EDTAMZNStocks with implied volatility above IV index mean; GT AMZN
Subscribe for More Information
06:03 EDTAMZNAmazon Fresh now available in select areas in New York
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use